Department of Medical and Surgical Sciences, University Of Foggia, Foggia, Italy.
Department of Medical and Surgical Sciences, University Of Foggia, Foggia, Italy.
J Neuroimmunol. 2018 Oct 15;323:43-48. doi: 10.1016/j.jneuroim.2018.07.008. Epub 2018 Jul 17.
Recently, microvesicles (MVs) were considered as important mediators of intercellular communication, especially in pathological conditions as Multiple Sclerosis (MS). In myeloid cells, MV shedding is induced by the receptor P2X7 with the involvement of acid sphingomyelinase (A-SMase) and release of the IL-1β. In this study we evaluate how Fingolimod affects MVs production by the monocytes, as well as P2X7R, IL-1β expression and A-SMase activity. Treatment decreased MVs production and IL-1β expression. This effect was associated with the inhibition of A-SMase activity in BzATP-stimulated monocytes from MS patients. These evidences suggest monocyte MVs as a possible disease and drug-efficacy biomarkers.
最近，微泡（MVs）被认为是细胞间通讯的重要介质，尤其是在多发性硬化症（MS）等病理条件下。在髓样细胞中，MV 的脱落是由 P2X7 受体诱导的，涉及酸性鞘磷脂酶（A-SMase）和白细胞介素-1β（IL-1β）的释放。在这项研究中，我们评估了 fingolimod 如何影响单核细胞产生 MV，以及 P2X7R、IL-1β 表达和 A-SMase 活性。治疗降低了 MV 的产生和 IL-1β 的表达。这种效应与 BzATP 刺激的 MS 患者单核细胞中 A-SMase 活性的抑制有关。这些证据表明单核细胞 MV 是一种潜在的疾病和药物疗效生物标志物。
